Disease · MONDO_0019954
pancreatic neuroendocrine tumor
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. pancreatic neuroendocrine tumor. Diseases, record MONDO_0019954. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019954
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
islet cell tumor, islet cell tumors - pancreas, islet cell tumors of the pancreas, islet cell tumour, islet cell tumours - pancreas, islet cell tumours of the pancreas, pancreatic NET, well differentiated pancreatic endocrine neoplasm, well differentiated pancreatic endocrine tumor, well differentiated pancreatic endocrine tumour, well-differentiated NEN of pancreas, well-differentiated neuroendocrine neoplasm of pancreas, well-differentiated pancreatic NEN, well-differentiated pancreatic neuroendocrine neoplasm
- Open Targets
Drugs54
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BELZUTIFAN | CHEMBL4585668 | Small molecule | Approval | FDA | 1 | 0 | 0 | Drugs and targets |
| EVEROLIMUS | CHEMBL1908360 | Small molecule | Phase 3 | ClinicalTrials.gov | 15 | 15 | 15 | Drugs and targets |
| TEMOZOLOMIDE | CHEMBL810 | Small molecule | Phase 3 | ClinicalTrials.gov | 14 | 14 | 14 | Drugs and targets |
| CAPECITABINE | CHEMBL1773 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| STREPTOZOCIN | CHEMBL1977579 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| SURUFATINIB | CHEMBL4297190 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| SUNITINIB MALATE | CHEMBL1567 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| SOMATOSTATIN | CHEMBL1823872 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| SUNITINIB | CHEMBL535 | Small molecule | Phase 2 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
1 to 10 of 54
See all 54 drugsTargets107
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| KDR | Vascular endothelial growth factor receptor | 7 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 6 | Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 6 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| SSTR1 | Somatostatin receptor | 5 | Somatostatin receptor 1 agonist; Somatostatin receptor agonist; Somatostatin receptor binding agent | Phase 3 | https://conductscience.org/library/genes/6751 | Drugs and targets |
| SSTR2 | Somatostatin receptor | 5 | Somatostatin receptor 2 agonist; Somatostatin receptor agonist; Somatostatin receptor binding agent | Phase 3 | https://conductscience.org/library/genes/6752 | Drugs and targets |
| SSTR3 | Somatostatin receptor | 5 | Somatostatin receptor 3 agonist; Somatostatin receptor agonist; Somatostatin receptor binding agent | Phase 3 | https://conductscience.org/library/genes/6753 | Drugs and targets |
| SSTR5 | Somatostatin receptor | 5 | Somatostatin receptor 5 agonist; Somatostatin receptor agonist; Somatostatin receptor binding agent | Phase 3 | https://conductscience.org/library/genes/6755 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 4 | Stem cell growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 4 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| SSTR4 | Somatostatin receptor | 4 | Somatostatin receptor agonist; Somatostatin receptor binding agent | Phase 3 | https://conductscience.org/library/genes/6754 | Drugs and targets |
1 to 10 of 107
See all 107 targetsTrials63
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00510068 | Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors | Phase 3 | 410 | 2011-12-15 | Advanced Neuroendocrine Tumors of Pancreatic Origin | EVEROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT00428597 | A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors | Phase 3 | 171 | 2010-10-11 | Carcinoma, Islet Cell, Carcinoma, Pancreas | SUNITINIB MALATE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00363051 | Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy | Phase 2 | 160 | 2012-03-30 | Islet Cell Carcinoma, Neuroendocrine Carcinoma, Neuroendocrine Tumor, Pancreatic Neoplasms | EVEROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT01374451 | Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET | Phase 2 | 160 | 2016-12-20 | Islet Cell Tumor | EVEROLIMUS, PASIREOTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01229943 | Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery | Phase 2 | 150 | 2016-02-11 | Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor, Pancreatic Gastrinoma, Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2, Pancreatic Vipoma | BEVACIZUMAB, EVEROLIMUS, OCTREOTIDE ACETATE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01824875 | Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors | Phase 2 | 144 | 2022-10-19 | Gastrinoma, Glucagonoma, Insulinoma, Islet Cell Carcinoma, Pancreatic Polypeptide Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma | CAPECITABINE, TEMOZOLOMIDE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02264665 | OPALINE : A Study Of Morbidity And Mortality At 2 Years | 144 | 2023-11-13 | Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive | EVEROLIMUS, SUNITINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT02246127 | Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor | Phase 3 | 141 | 2025-05-11 | Neuroendocrine Tumors | EVEROLIMUS, FLUOROURACIL, STREPTOZOCIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02549937 | A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors | Phase 1/2 | 130 | 2024-07-10 | Tumors | SURUFATINIB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02678780 | Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors | Phase 2 | 123 | 2025-07-24 | Neuroendocrine Tumors | LENVATINIB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 63
See all 63 trialsComparisons in its trials16
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Everolimus vs STZ - 5FU: deaths from any cause | 26 of 105 | 35 of 104 | 209 | NCT02246127 | Trial comparisons |
| Everolimus vs STZ - 5FU: serious adverse events | 28 of 105 | 26 of 104 | 209 | NCT02246127 | Trial comparisons |
| Sunitinib vs Placebo: serious adverse events | 22 of 83 | 34 of 82 | 165 | NCT00428597 | Trial comparisons |
| Stratum 1: Everolimus 10 mg vs Stratum 2: Everolimus 10 mg + Octreotide Depot: serious adverse events | 63 of 115 | 27 of 45 | 160 | NCT00363051 | Trial comparisons |
| Everolimus LAR + Pasireotide vs Everolimus: serious adverse events | 41 of 78 | 49 of 81 | 159 | NCT01374451 | Trial comparisons |
| Arm I (Octreotide Acetate and Everolimus) vs Arm II (Octreotide Acetate, Everolimus, and Bevacizumab): serious adverse events | 20 of 74 | 31 of 73 | 147 | NCT01229943 | Trial comparisons |
| Arm A (Temozolomide) vs Arm B (Temozolomide and Capecitabine): deaths from any cause | 42 of 72 | 33 of 72 | 144 | NCT01824875 | Trial comparisons |
| Arm A (Temozolomide) vs Arm B (Temozolomide and Capecitabine): serious adverse events | 15 of 68 | 32 of 71 | 139 | NCT01824875 | Trial comparisons |
| Targeted Therapy at Inclusion vs Other Treatments at Inclusion: Number of Participants Who Had a Change in Their Treatment - Based on Targeted Therapy Group and Other Treatments Group at Inclusion | 44 of 55 | 68 of 79 | 134 | NCT02264665 | Trial comparisons |
| Neuroendocrine Tumors of the Pancreas vs Neuroendocrine Tumors of Gastrointestinal Tract: deaths from any cause | 21 of 55 | 29 of 56 | 111 | NCT02678780 | Trial comparisons |
1 to 10 of 16
See all 16 comparisons in its trialsPapers from its trials42
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019954
GET https://conductscience.org/api/diseases/v1/MONDO_0019954/drugs?page=2